Infinity Pharma (INFI) Reports Recent Publication of New Scientific Paper Further Supporting Hedgehog Pathway Inhibitor
More News related to INFI
- Infinity's IPI-504 Named One of Windhover and Campbell Alliance's "Top 10 Projects to Watch" in Oncology
- Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony
- Infinity to Present at Upcoming Conferences
- Infinity Pharma (INFI) Posts Q3 Loss of 36c, Beats Eatimates by 8c
- Infinity Reports Recent R&D Highlights and Third Quarter 2009 Results
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) announced the recent publication of a new scientific paper further supporting Hedgehog signaling pathway inhibition as a promising new approach to treat cancer. The data featured in the paper show that IPI-926, when administered in combination with gemcitabine in a preclinical mouse model of treatment-resistant pancreatic cancer, increased tumor cell death, resulting in a reduction of tumor size and increased survival. These data suggest that IPI-926 may enable chemotherapeutic agents to successfully access and kill tumor cells. Infinity is currently evaluating IPI-926 in a Phase 1 clinical trial in patients with advanced solid tumors.
The paper, lead-authored by Kenneth P. Olive, Ph.D., is titled "Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer" and was published in the online edition of the journal Science on May 21, 2009.
"It is promising to see these preclinical results, particularly in a disease setting as clinically challenging as pancreatic cancer," said Dr. David Tuveson, senior author and group leader in tumor modeling and experimental medicine at Cancer Research UK's Cambridge Research Institute. "For patients with pancreatic cancer, the need for new treatments -- especially those that could be used in combination to improve the activity of the current standards of care -- is critical."
"Unlocking the therapeutic potential of existing chemotherapeutic agents by inhibiting the Hedgehog pathway could prove to be a critical step in developing treatment for some of the most difficult cancers," said Vito Palombella, Ph.D., vice president of drug discovery, Infinity. "We are very encouraged by these early, but key, data with IPI-926. We are advancing IPI-926 through clinical development and continue to explore the biology of hedgehog pathway inhibition."
Related Categories
Corporate NewsStocks Mentioned
-0.30Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
